The Calcium-Binding Protein S100A6 Accelerates Human Osteosarcoma Growth by Promoting Cell Proliferation and Inhibiting Osteogenic Differentiation

• Published in: Cellular physiology and biochemistry Vol. 37; no. 6; pp. 2375 - 2392
• Main Authors: Li, Yasha, Wagner, Eric R., Yan, Zhengjian, Wang, Zhonliang, Luther, Gaurav, Jiang, Wei, Ye, Jixing, Wei, Qiang, Wang, Jing, Zhao, Lianggong, Lu, Shun, Wang, Xin, Mohammed, Maryam K., Tang, Shengli, Liu, Hao, Fan, Jiaming, Zhang, Fugui, Zou, Yulong, Song, Dongzhe, Liao, Junyi, Haydon, Rex C., Luu, Hue H., He, Tong-Chuan
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland Cell Physiol Biochem Press GmbH & Co KG 01.01.2015
• Subjects: Animals; Apoptosis; BMP9; Bone tumor; Cell Cycle Proteins - physiology; Cell Differentiation - physiology; Cell Line, Tumor; Cell Proliferation - physiology; Heterografts; Humans; Mesenchymal stem cells; Mice; Original Paper; Osteoblastic differentiation; Osteogenesis; Osteosarcoma; Osteosarcoma - pathology; S100 Calcium Binding Protein A6; S100 proteins; S100 Proteins - physiology; S100A6; Osteoblastic differentiation; S100 proteins; Bone tumor; Osteosarcoma; S100A6; BMP9; Apoptosis; Mesenchymal stem cells
• ISSN: 1015-8987; 1421-9778
• DOI: 10.1159/000438591

Background/Aims: Although osteosarcoma (OS) is the most common primary malignancy of bone, its molecular pathogenesis remains to be fully understood. We previously found the calcium-binding protein S100A6 was expressed in ∼80% of the analyzed OS primary and/or metastatic tumor samples. Here, we investigate the role of S100A6 in OS growth and progression. Methods: S100A6 expression was assessed by qPCR and Western blotting. Overexpression or knockdown of S100A6 was carried out to determine S100A6's effect on proliferation, cell cycle, apoptosis, tumor growth, and osteogenic differentiation. Results: S100A6 expression was readily detected in human OS cell lines. Exogenous S100A6 expression promoted cell proliferation in vitro and tumor growth in an orthotopic xenograft model of human OS. S100A6 overexpression reduced the numbers of OS cells in G1 phase and increased viable cells under serum starvation condition. Conversely, silencing S100A6 expression induced the production of cleaved caspase 3, and increased early stage apoptosis. S100A6 knockdown increased osteogenic differentiation activity of mesenchymal stem cells, while S100A6 overexpression inhibited osteogenic differentiation. BMP9-induced bone formation was augmented by S100A6 knockdown. Conclusion: Our findings strongly suggest that S100A6 may promote OS cell proliferation and OS tumor growth at least in part by facilitating cell cycle progression, preventing apoptosis, and inhibiting osteogenic differentiation. Thus, it is conceivable that targeting S100A6 may be exploited as a novel anti-OS therapy.